Schering-Plough is bullish about its experimental anti-clotting drug, saying it could be a potentially transformational product that can significantly reduce the risk of heart attack and stroke without raising the risk of bleeding. The drug prevents thrombin, a clot-causing protein, from attaching to platelets. Report